Hevolution Foundation to Host Panel on Healthspan Investing at 2023 BIO International Convention
01 Jun 2023
RIYADH, Saudi Arabia--(BUSINESS WIRE)--Hevolution Foundation, a global non-profit organization that provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science, announces its participation at the upcoming BIO International Convention, taking place at the Boston Convention Center, June 5-8, 2023. As part of its commitment to advancing healthspan research and entrepreneurship, Hevolution will be hosting a thought-provoking panel discussion, "Healthy Returns: Healthspan Investment Comes of Age."
'Healthy Returns: Healthspan Investment Comes of Age.'
The session, scheduled for Tuesday, June 6th at 3:00pm ET, will be moderated by William Greene, MD, Chief Investment Officer of Hevolution Foundation. Esteemed authorities from the biopharmaceutical and investment fields will serve as panelists:
Jens Eckstein, PhD, Managing Partner at Apollo Health Ventures
Alexander Fleming, MD, Founder and Chairman of Kinexum, and former head of metabolic disease review at the FDA
Kristen Fortney, PhD, Founder and CEO of BioAge Labs
Andrew Levin, MD, PhD, Managing Director at RA Capital
John McDonald, Corporate Vice President of Global R&D Business Development at Novo Nordisk
The world is facing a demographic crisis, marked by the challenges posed by unhealthy aging. As societies age rapidly while fertility rates decline, there is a pressing need to extend the healthy years of life, also known as healthspan. This imperative also presents a unique opportunity for biopharma investors to make a substantial impact on the future of healthcare and society, and it may represent one of the biggest investment opportunities of the 21st Century.
The discussion will delve into the ongoing evolution of healthspan research from a niche field towards being a central focus of the biopharmaceutical industry, potentially driving the next wave of R&D innovation. The session will explore the promises and potential pitfalls for investors in this burgeoning sector. Additionally, panelists will address growing pains in the field and propose strategies to overcome them, unveil emerging areas of investment focus, and share their insights into the future of healthspan research and its implications for biopharma investors.
"We are excited to host this distinguished panel of experts at the BIO International Convention," commented Dr. Greene. "The discussion promises to shed light on the transformative power of healthspan investment and its potential to shape the future of healthcare. We invite BIO attendees to join us as we explore the unique opportunities and challenges in this rapidly evolving field."
More information:
The panel session “Healthy Returns”
The BIO International Convention
About Hevolution Foundation
Founded in the belief that every person has the right to live a longer, healthier life, Hevolution Foundation is a global catalyst, partner, and convener, on a mission to drive efforts to extend healthy human lifespan and understand the processes of aging. Hevolution Foundation aims to increase the number of aging-related treatments on the market, compress the timeline of drug development, and increase accessibility to therapeutics that extend healthy lifespan, also known as healthspan. A non-profit organization headquartered in Riyadh, with an annual budget of up to $1 Billion, Hevolution Foundation plans to open hubs in North America and other global locations to support a cutting-edge, global ecosystem of talent to propel aging and geroscience research forward and achieve medical breakthroughs to help humanity live healthier, longer.
Connect with Hevolution Foundation on LinkedIn, Twitter and at Hevolution.com.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.